Modernization of Cosmetics Regulation Act of 2022 (MoCRA): Why the “just update the label” view is wrong
The headline brands should be paying attention to right now is the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) from the U.S. Food and Drug Administration. Many skincare executives still treat MoCRA as a paperwork event: revise a few INCI names, confirm the responsible person, file what FDA asks for, and move on. That is the conventional wisdom. It is also too narrow for 2026. In the United States, MoCRA is not merely a regulatory update; it is a filter that changes who can enter, who can scale, and who gets penalized when operations, claims, labels, and channel strategy are not aligned.
The contrarian view is simple: the biggest US skincare compliance risk in 2026 is not failing to “meet the rules” on paper. It is building a market entry strategy that assumes compliance is a back-office function. For global brands, especially those expanding from Europe, Canada, Australia, Korea, or Latin America, the real exposure sits at the intersection of formula substantiation, adverse event handling, ecommerce content, import economics, and retailer readiness. MoCRA matters now because it gives FDA more structure, more visibility, and more practical levers over cosmetics businesses selling into the United States. That changes launch economics, not just legal checklists.
The common assumption: US skincare compliance is lighter than Europe, so market entry is easier
For years, founders repeated a familiar line: the United States is a large but relatively flexible beauty market. Compared with the EU’s pre-market architecture, the US looked more permissive, especially for skincare positioned as cosmetics rather than drugs. That belief encouraged speed-first launches, distributor-led expansion, and “fix it later” labeling. Many international brands concluded that if they could survive a stricter jurisdiction elsewhere, US compliance would be manageable.
That assumption now breaks down in practice. FDA’s MoCRA framework formalizes requirements around facility registration, product listing, adverse event recordkeeping, safety substantiation, and contact information on labels for adverse event reporting. None of those requirements exists in a vacuum. Each one touches another commercial function. If a skincare brand cannot connect complaint handling with batch traceability, or ecommerce claims with product classification risk, then “compliance” fails operationally long before FDA issues a letter.
There is also a market incentive to get this right. Circana reported that the US beauty industry in H1 2026 saw prestige beauty up 7%, showing that brands still have room to capture growth in a highly competitive environment. But that same growth means more scrutiny from retailers, marketplaces, and acquirers. In a growth market, weak compliance systems do not stay hidden; they become due diligence issues, listing barriers, and margin drains.
The better framing for 2026 is this: the United States is still a huge skincare opportunity, but it is no longer a forgiving one for underprepared brands. Easier does not mean easy. Lighter pre-approval does not mean lower exposure.
MoCRA is not mainly a legal story. It is a systems story.
Most brands respond to regulatory change by asking legal counsel what must be filed. That is necessary but incomplete. The more useful question is operational: what data, controls, and workflows must exist so the business can prove what it says, trace what it sells, and react when something goes wrong?
Under MoCRA, skincare brands need to think in systems. A label is tied to the responsible person. The responsible person is tied to adverse event handling. Adverse events are tied to records, formulations, manufacturing details, and distribution channels. Product listings are tied to SKU discipline. Safety substantiation is tied to supplier documentation and claim language. If these pieces live in separate spreadsheets across a founder, a contract manufacturer, a distributor, and an Amazon agency, the brand may technically know the rules but still fail execution.
This is where many global expansion plans stall. A founder may assume the US problem is translation and packaging artwork. In reality, the harder problem is assembling a defendable compliance file across every SKU and every claim. A cleanser that says “soothes eczema-prone skin,” a serum marketed as “anti-inflammatory,” or a moisturizer promising “barrier repair at the cellular level” can drift from cosmetic positioning toward drug implications depending on context. The issue is not just what appears on the carton. It is what appears on Amazon bullets, paid social captions, influencer scripts, and PDP FAQs.
That is why brands entering the market should audit more than labels. They should audit the full commercial expression of the product. Tools like an AI Label Compliance Analysis ($599) or an Amazon Listing Audit are most valuable when used together, because the US enforcement and platform-risk problem often starts where the marketing team thinks it is being persuasive.
The real bottleneck in 2026 is not formula approval. It is claims discipline.
Another widespread assumption is that skincare compliance is mostly about ingredients: banned substances, allergens, preservatives, and nomenclature. Ingredients matter, but in the US market the faster route to trouble is often claims. Brands love to focus on what is in the bottle because that feels technical and controllable. FDA, plaintiffs’ lawyers, retailers, and consumers also pay attention to what the brand promises.
This matters more in skincare than in many adjacent beauty categories because skincare sits close to the border between cosmetic and drug claims. A brand can unintentionally reposition a cosmetic product into higher-risk territory through scattered messaging. One ad says “calms redness.” Fine. Another says “treats rosacea symptoms.” Problem. One product page says “supports clearer-looking skin.” Fine. Another says “stops acne-causing bacteria.” Problem. The classification risk is cumulative and channel-specific.
McKinsey’s 2030 beauty growth analysis highlights how beauty demand is shifting across channels, concepts, and digitally influenced discovery. For brands, that has a direct compliance consequence: the label is no longer the only high-risk communication surface. As beauty moves “from aisle to algorithm,” product claims multiply across retailer PDPs, marketplaces, affiliate content, creator-led tutorials, and AI-generated search summaries. In other words, distribution expansion creates compliance expansion.
The contrarian lesson is that brands should stop treating US label requirements as the center of the compliance universe. They are only one layer. A beautiful compliant carton attached to a reckless digital claims strategy is not compliant in any commercially meaningful sense. For many skincare brands, the first serious US compliance upgrade should be a claims governance protocol, not a packaging refresh.
“Clean,” “organic,” and “natural” are not shortcuts to lower risk
Founders often assume that cleaner positioning reduces regulatory friction. If the formula is plant-based, certified organic, fragrance-free, or minimalist, they expect an easier path. That instinct is understandable, but misleading. Softer positioning can reduce some reputational concerns while increasing substantiation and labeling complexity in other areas.
Take organic positioning. Red Pantz recently marked five years as a fully USDA-certified organic skincare line with CCOF. That is a meaningful achievement and a strong market signal, but it also illustrates a broader point: credible “organic” status in the US is not a casual marketing descriptor. It requires program discipline, certification structure, and consistency. Brands that use “organic,” “non-toxic,” or “free-from” language loosely may create exactly the kind of substantiation and consumer-expectation mismatch that attracts scrutiny.
Similarly, “clean beauty” language is not a regulatory shield. It can create pressure to defend absence claims, sustainability language, or comparative safety implications. If a brand says “chemical-free,” “toxin-free,” or “preservative-free” without precision, it may trigger challenges from competitors, watchdogs, platforms, or consumers. The more emotionally loaded the promise, the stronger the evidence burden becomes.
The practical takeaway is uncomfortable for many marketing teams: premium ethical positioning often increases, not decreases, the need for disciplined compliance review. If your US market entry thesis depends on trust markers, then your documentation and wording must be unusually tight. This is exactly where a US Market Snapshot ($349) can help identify which claims are common, credible, and commercially expected in your segment before the creative team overcommits.
Tariffs, retailer standards, and Amazon rules now matter almost as much as FDA rules
One of the most outdated beliefs in global expansion is that “regulatory compliance” means government compliance alone. In the United States in 2026, that is too narrow to be useful. Market entry lives inside a stack of requirements: FDA expectations, customs realities, retailer onboarding standards, marketplace content rules, and state-level commercial pressures. A brand can be legally sellable and still commercially blocked.
Recent trade friction underlines the point. Personal Care Insights reported that some Canadian cosmetics faced a 50% US duty as USMCA protection failed. Whether a particular skincare brand is directly affected or not, the strategic message is clear: cross-border beauty expansion into the US is not governed by one rulebook. Duty exposure, landed cost changes, and sourcing assumptions can rapidly alter pricing, margin, and channel viability. A product that looked competitive before import complications may no longer fit prestige, masstige, or Amazon price architecture.
Retailers and marketplaces add another layer. Big-box buyers increasingly expect clean documentation, contact details, traceability, and category consistency. Amazon may suppress, flag, or restrict listings based on wording, imagery, missing fields, or perceived medical claims long before FDA enters the picture. This is why a brand should map compliance risk channel by channel. DTC, Amazon, specialty retail, and distributor-led wholesale each carry different operational choke points.
For many companies, the best use of budget is not to overinvest in one legal memo but to buy decision-grade market intelligence before launch. A full US Launch Report ($599) can be more valuable than another packaging round if it helps leadership see the combined effect of regulation, pricing, channel fit, and competitor claims standards. In 2026, the winning brands are not merely compliant. They are compliance-literate in commercial terms.
What brands should do differently: build a US compliance growth model, not a filing checklist
If the old model was “enter first, standardize later,” the 2026 model should be the reverse. Brands need a US compliance growth model that connects product, marketing, operations, and channel management from day one. That sounds heavier, but it often saves money by preventing relabeling, listing disruption, returns, and distributor conflict.
Start with a structured pre-entry review. Before printing labels or signing a 3PL, confirm the intended US classification of each skincare SKU, the exact claims set by channel, the responsible person setup, the quality of safety substantiation, the complaint escalation process, and the import pathway. Then test whether the story your brand wants to tell matches what the US market rewards. A serum can be beautifully formulated and still commercially mispositioned if its claims are too timid for prestige, too risky for Amazon, or too vague for derm-led retail.
Next, centralize your source of truth. Product data, substantiation, artwork, and claims language should not live in disconnected agency folders. This is where a repository like BrandVault becomes useful: one place to manage the materials your marketing, regulatory, and channel teams actually need. Layer on Industry Intel if you want to monitor how the competitive set is talking about similar products, ingredients, and compliance-sensitive claims in the US.
Most importantly, train the commercial team. Founders often assume compliance belongs to legal or quality. In reality, your biggest risk may come from a copywriter, marketplace manager, influencer brief, or sales deck. Everyone touching the brand message should understand which words move a skincare product toward cosmetic safety, therapeutic implication, or unsupported superiority claims.
Below is a practical 2026 framework for skincare brands entering or scaling in the United States:
| Area | Common assumption | 2026 reality | What to do |
|---|---|---|---|
| Labels | Packaging is the main compliance task | Labels are only one risk surface | Review carton, PDPs, ads, Amazon bullets, and influencer scripts together |
| Claims | Ingredient quality reduces scrutiny | Claims language drives classification and substantiation risk | Create an approved claims hierarchy for each SKU and channel |
| Operations | Regulatory can be outsourced after launch | Adverse events, traceability, and records need active internal ownership | Name an accountable US compliance lead before launch |
| Channels | If FDA is satisfied, retail will be fine | Retailers and Amazon apply their own content and documentation standards | Conduct channel-specific audits before listings go live |
| Global expansion | US is easier than Europe | US is less pre-approval-heavy but more fragmented in commercial enforcement | Budget for market intelligence, claim review, and import planning together |
The bottom line: MoCRA raises the cost of being sloppy, not the cost of being ambitious
The lazy reading of MoCRA is that the United States has become harder for skincare brands. The smarter reading is more useful: the US has become harder for undisciplined brands. That is not the same thing. Well-prepared companies can still move quickly, differentiate clearly, and scale profitably. In fact, as weaker entrants struggle with claims creep, relabeling, marketplace suppression, and documentation gaps, better-prepared brands can gain share.
US skincare remains attractive. Global Market Insights continues to project strong growth for cosmetics and beauty through 2035, and the US remains one of the few markets where premiumization, digital discovery, and retailer fragmentation create room for both niche and scaled brands. But opportunity now belongs to brands that understand compliance as part of market entry strategy, not as a cleanup task after marketing decisions have already been made.
If your team is planning US expansion, do not ask only, “Are we compliant?” Ask harder questions: Can we defend every meaningful claim? Can we trace every unit? Can we survive an adverse event escalation? Can our Amazon content pass scrutiny? Can our landed cost still support our target channel? That is the real 2026 skincare compliance brief in the United States.
If you want a faster answer specific to your brand, get a personalized US Launch Intelligence Report or start with a free Brand Readiness Score. It is the quickest way to see whether your skincare line is genuinely ready for US market entry, not just technically labeled for it.